Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services NYSE: GRDN reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions. Chief Executive Officer Fred Burke said first-half reported revenue rose 2%, but would have increased by a low-double-digit percentage without IRA pricing reductions. Adjusted EBITDA for the first half increased 23% from the year-earlier period, according to the company. Based on first-half performance and expectations for the rest of the year, Guardian raised its 2026 outlook. The company now expects revenue of $1.43 billion to $1.45 billion, compared with its prior range of $1.40 billion to $1.42 billion. It raised projected adjusted EBITDA to $129 million to $131 million from $123 million to $127 million. Chief Financial Officer Will Mudd said revenue in the quarter benefited from organic growth, acquisitions, higher resident acuity, plan optimization efforts, and favorable product and payer mix. Residents served at quarter-end exceeded 210,000, increasing by a high-single-digit percentage year over year, while prescription volumes also rose by a high-single-digit percentage. Gross profit rose 18% to $80 million, resulting in a gross margin of 22.8%, despite higher fuel costs. Selling, general and administrative expenses were $56.5 million, or 16.9% of revenue. Guardian recorded net income of $22.1 million, compared with $8.8 million in the prior-year quarter. The quarter’s net income included an $8.5 million cash payment from the settlement of a payer dispute, which was recorded as other income and excluded from adjusted EBITDA because the company said it was not representative of ongoing operating performance. Mudd said acquisitions and greenfield locations launched in 2024 and 2025 remained below Guardian’s corporate margin and reduced consolidated margin by roughly 60 basis points in the second quarter. That was an improvement from an estimated 80-basis-point impact in the first quarter. For the second half, the company expects reported revenue to decline year over year by a low-single-digit percentage because of continued IRA-related pricing reductions. Excluding those reductions, underlying revenue growth is expected to remain in the high-single digits. Guardian expects adjusted EBITDA margin to be relatively stable in the third quarter and to increase seasonally in the fourth quarter due to vaccine activity. Burke said the next tranche of IRA pricing reductions is expected to have a smaller revenue effect than the 2026 tranche. He said the company expects the next group to represent roughly 40% of the 2026 tra.